Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized ...

Patients with EGFR pathway and Fusion Positive mutations had higher Healthy Eating Index-2020 scores than U.S. reference.

Treatment for EGFR-Sensitive Mutation NSCLCNumerous EGFR-TKIs are approved for EGFR-sensitive mutation NSCLC, including gefitinib, erlotinib ...

Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...

The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

The relation between body mass index, comorbidity, choice of surgery, and prognostic factors in early breast cancer: Data from a nation-wide Danish cohort No significant financial relationships to ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...

Two microscopy images of human colon organoids. The left image shows an organoid with the FBXW7 mutation (colorectal cancer) and the right image shows an organoid without the mutation (wild type). The ...

Using a powerful single-molecule imaging method they developed, a Broad Institute research team has unveiled a dynamic view ...